HIMS Stock Outlook 2026: Can Hims & Hers Survive the GLP-1 Pivot?

The Pivot That Will Define HIMS

Hims & Hers Health built its growth story on a simple, powerful insight: consumers will pay a subscription for convenient, stigma-free access to medications they’re embarrassed to discuss in person. Hair loss. Erectile dysfunction. Weight gain. The company turned telehealth into a software-margin business — until the FDA pulled the rug.

After losing its most explosive growth driver (compounded semaglutide), HIMS now faces the question every transition-period company faces: is this a speed bump or an inflection point? The 2026 data, so far, points to both.

I’ve been following HIMS since its SPAC listing. The core tension in this stock has always been: is the platform the product, or is cheap medication the product? How you answer that question determines whether you view 2026 as a stress test the company passes or a crisis that exposes structural dependency on regulatory arbitrage.

---

Business Model: Why the Margins Were So Good

HIMS operates three interlocking layers:

Layer 1 — Async telehealth subscription. Patients answer a symptom questionnaire, get matched with a licensed physician, and receive a treatment plan. No insurance, no waiting room. This entry point locks in a monthly subscription.

Layer 2 — Captive pharmacy. HIMS fills prescriptions through its own pharmacy network, sourcing generic active pharmaceutical ingredients at commodity prices. Before the GLP-1 shift, this generated gross margins above 73%.

Layer 3 — Category expansion. A single app covers hair loss, ED, skin, mental health, and weight loss. Cross-sell between categories increases average revenue per user over time.

This stack is why 2024 gross margins hit 79% — unusually high for any healthcare company. The GLP-1 compounding play pushed that further until regulators stepped in.

What made the model so durable outside of GLP-1: customers who came in for ED treatment often stay for hair loss products. Those who started with dermatology might add mental health. Monthly recurring revenue across multiple categories meant that even if one revenue stream contracted, the subscriber base remained sticky. The average monthly revenue per subscriber reached $83 in Q4 2025 — representing meaningful cross-category attachment.

That diversification is exactly why the post-compounding story is not a death knell for HIMS. The platform existed before GLP-1, and continues to grow outside of it.

---

The Numbers That Matter: Q1 2026 and Full-Year 2025

Full-Year 2025 (Verified)

Hims & Hers reported 2025 annual revenue of $2.35 billion, up 59% year-over-year. Subscriber count exceeded 2.5 million. Adjusted EBITDA came in at $318 million. Q4 2025 alone delivered $618 million in revenue (+28% YoY), with monthly revenue per subscriber of $83 in Q4.

Q1 2026: The Transition Quarter

Metric	Q1 2026	Q1 2025	Change
Total Revenue	$608.1M	~$586M	+4%
U.S. Revenue	$529.9M	—	-8% YoY
International Revenue	$78.2M	—	+969% YoY
Gross Margin	65%	73%	-8pp
Adjusted EBITDA	$44.3M	$91.1M	-51%
Net Income (Loss)	-$92.1M	+$49.5M	Reversal
Subscribers	2.6M	—	+9% YoY

Source: HIMS Q1 2026 8-K filed with SEC EDGAR, May 2026

The net loss included $33.5 million in one-time restructuring charges tied to winding down compounded GLP-1 operations. Even adjusted, the EBITDA margin halved. Management called 2026 a “defining year.” That’s corporate-speak for “painful but necessary.”

Crucially, HIMS raised full-year 2026 guidance to $2.8–3.0 billion in revenue and $275–350 million in adjusted EBITDA — signaling confidence the branded model can offset the compounding revenue loss.

---

The GLP-1 Regulatory Saga: A Timeline

The compounding story is complex. Here’s the condensed version:

Background: FDA allows compounding pharmacies to produce drugs from bulk APIs when those drugs are on the shortage list. HIMS exploited this to sell semaglutide at a fraction of Wegovy’s list price.

February 5, 2026: HIMS announces a compounded oral semaglutide pill. The market briefly cheers.

February 6, 2026: FDA publicly announces intent to restrict mass-marketed non-FDA-approved GLP-1 products — within 24 hours of the HIMS announcement.

February 7, 2026: HIMS stops selling compounded semaglutide. HHS refers the company to the DOJ for potential federal law violations.

April 30, 2026: FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, citing no clinical need for outsourcing compounding.

Current: Novo Nordisk is suing HIMS over compounded products marketed as competing with Wegovy and Ozempic.

The regulatory environment is now unambiguous. Compounded GLP-1 mass marketing is effectively over.

---

The Branded Pivot: Does It Work?

HIMS moved quickly. Partnerships with Novo Nordisk (NVO) and Eli Lilly (LLY) now give HIMS access to Wegovy, Ozempic, Zepbound, Mounjaro, and Foundayo through its platform.

The Wegovy launch produced 125,000+ shipments in six weeks — a genuine operational milestone. International revenue spiked 969% YoY in Q1, partly reflecting the Eucalyptus acquisition in markets like Australia and the UK where the regulatory environment differs.

The structural challenge: branded drug intermediation earns lower margins than compounding. HIMS is essentially becoming a high-convenience pharmacy front-end for Novo and Lilly. The question is whether platform stickiness (subscriptions, personalization, async consults) sustains pricing power over time.

The bearish reading: as Wegovy supply expands and retail pharmacy access improves, HIMS’s subscription premium for GLP-1 access erodes. Citi’s Sell rating ($30 target) rests on exactly this view.

The bullish reading: HIMS’s platform — not the drug itself — is the moat. Subscribers stay for the experience, the consolidated health dashboard, and the stigma-free interface. JPMorgan called it a “compelling path” post-Q1. Barclays sees it as the “Netflix of healthcare.”

---

Competitive Landscape: Who’s Really Threatening HIMS?

The competitive map for HIMS in 2026 is more complex than it appears, because competition comes from three completely different directions simultaneously.

Direct D2C Competitors

Ro (Roman Health): The closest comparable — same categories (ED, hair loss, weight), same D2C subscription model, same pharmacy-integrated approach. Ro is private, so no public financials, but the business model is essentially identical. The GLP-1 crackdown hit Ro similarly, which means neither company gained a structural competitive edge from the regulatory change — both are navigating the same pivot.

Nurx / Nuo: Focused primarily on women’s health, contraception, and dermatology. Narrower scope than HIMS, but overlap is meaningful in skin care and mental health subscriptions. Less exposed to GLP-1 risk.

PlushCare: Primary care-focused telehealth that accepts insurance, making it a different customer segment but competing for the same consumer mindshare around convenient remote healthcare.

The Amazon Wildcard

Amazon One Medical rolled out bundled medical treatment services in 2026, directly competing in the telehealth-to-pharmacy pipeline that HIMS built from scratch. This is the competitor that keeps HIMS management awake at night — and for good reason.

Amazon’s advantages are structural: Prime membership loyalty covering hundreds of millions of households, last-mile logistics that can match or beat any specialty pharmacy, deep consumer purchase-history data to inform health recommendations, and the ability to cross-subsidize entry into new markets for years. Amazon One Medical’s bundled service was already competitive with Ro and HIMS on price before GLP-1 became the battleground.

The counter-argument: HIMS’s subscribers are paying for an integrated, stigma-free health experience with a consistent physician relationship — something Amazon’s transaction-focused model struggles to replicate. Platform stickiness is real. But it’s not guaranteed.

The Ironic Competition: Branded GLP-1 Suppliers

This is the most uncomfortable dynamic in the HIMS story: Novo Nordisk (NVO) and Eli Lilly (LLY) are simultaneously HIMS’s distribution partners and potential direct competitors. Both pharma giants are watching the D2C telehealth space carefully. If Novo decides Wegovy should be available directly from novonordisk.com with a telehealth consult bundled in, HIMS’s intermediary role shrinks.

For now, the major branded GLP-1 makers benefit from HIMS’s distribution capabilities and subscriber base. The question is whether that partnership remains mutually beneficial as the branded market matures and supply constraints ease.

There’s also a longer-horizon wildcard worth noting for readers who follow the broader obesity and metabolic health space: mRNA-based metabolic vaccines in development — including programs at companies like Moderna (MRNA) — could eventually change the nature of GLP-1 treatment altogether. That’s a 2028–2030 story, not 2026, but directionally relevant.

---

Bull / Base / Bear Scenarios for 2026–2027

Bull Case: The Netflix of Healthcare Thesis

The “Netflix of healthcare” label that JPMorgan applied post-Q1 captures this scenario. Branded GLP-1 ramp accelerates materially in H2 2026 as Wegovy and Zepbound become the default path for weight-loss subscribers who want managed, supported treatment — not just a prescription. International revenue, already +969% in Q1, reaches 20%+ of total annual revenue as the Eucalyptus-backed expansion in Australia, the UK, and Europe gains scale. Hair/ED/mental health subscriber counts grow to 3+ million, providing a stable high-margin revenue base. Full-year gross margin recovers toward 69–71%. Full-year EBITDA hits the upper band of guidance ($350M). With durable 12–15% EBITDA margins and $3B revenue in sight, the stock re-rates toward 3–4x forward revenue. Price target: $45–55.

Base Case: Credible Transition, Patient Recovery

Full-year revenue lands in the $2.8–2.9B range. Gross margin stabilizes at 66–68% — below historical peaks but above Q1 2026 trough. Novo Nordisk lawsuit resolves through settlement without material financial penalty or operational restriction. Adjusted EBITDA $275–320M, within guidance. U.S. subscriber count grows modestly; international offset is real but not transformative yet. The stock trades range-bound in the $22–35 range while the market waits for two consecutive quarters of margin recovery to confirm durability. This is the most likely scenario over a 12-month horizon. Price target: $28–38.

Bear Case: Structural Model Break

The FDA finalizes semaglutide’s exclusion from the 503B Bulks List and uses it as a template for broader telehealth enforcement. The Novo Nordisk lawsuit produces an adverse judgment with meaningful damages — financial and reputational. Amazon One Medical aggressively prices branded GLP-1 access below HIMS’s subscription cost, capturing a measurable portion of new weight-loss subscribers. Without compounding economics and with commodity branded-drug intermediation margins, the EBITDA path narrows sharply. Full-year adjusted EBITDA misses guidance by 20–30%. The stock tests $15–18. This scenario requires several negative events to coincide — lower probability, but non-trivial given the regulatory velocity of 2026.

---

Valuation Framework: How to Think About HIMS’s Price

Traditional healthcare company metrics don’t fit HIMS well. It’s not a pharma with a pipeline, not a hospital with capex cycles, and not a pure SaaS with 80%+ net revenue retention. It’s a hybrid — part subscription platform, part pharmacy, part telehealth provider.

The most useful frame: price-to-forward-revenue (P/S) adjusted for margin trajectory.

At the $2.8–3.0B guidance midpoint and current trading levels, HIMS trades at roughly 1.0–1.5x forward revenue — historically cheap for a D2C subscription business with 65%+ gross margins, even accounting for the transition. The problem is that investors don’t know whether those 65% margins are a floor or a ceiling. If branded GLP-1 intermediation becomes the primary business, 65% may be optimistic long-term.

A worked scenario on EV/EBITDA: if HIMS delivers $300M adjusted EBITDA in 2026 (within guidance), and the market ascribes a 20x multiple — aggressive but consistent with high-growth healthcare tech — you get to approximately $6B enterprise value. Subtract net debt (minimal) and you’re in the $25–28 share price range at that multiple. A 25x multiple gets you to $33–35. These are not conservative numbers, but they’re not fantasy either.

The practical implication: at current prices, HIMS is not priced for perfection — it’s priced for execution that’s merely competent, not spectacular. That creates asymmetric upside if management delivers.

Tax Note for U.S. Investors

HIMS pays no dividend, so there’s no immediate dividend tax exposure. Capital gains are the primary tax consideration:

• Short-term (held < 1 year): taxed as ordinary income (up to 37% for high earners)
• Long-term (held > 1 year): taxed at 0%, 15%, or 20% depending on income bracket, plus 3.8% NIIT for high earners

Given the transition uncertainty, this is a stock many investors will hold through volatility — making the long-term hold case from a tax perspective compelling if you believe in the platform thesis.

Tax-advantaged accounts (401k, Roth IRA) are natural homes for high-volatility, high-upside growth names like HIMS. The volatility in HIMS — swings of 20–40% on regulatory news have been common in 2026 — makes tax-loss harvesting opportunities real. Investors holding HIMS in taxable accounts should track their cost basis carefully.

One additional note: HIMS has been known to do equity issuances to fund growth. Dilution risk is worth monitoring in quarterly filings. At current cash generation levels, near-term dilution looks unlikely, but it’s a standing risk for any growth-stage company.

---

Analyst Pulse: Where Wall Street Stands

After Q1 2026, the analyst community fractured in a way that’s unusual even for a volatile growth stock. The bull-bear range tells you something important about the fundamental uncertainty:

• Barclays: Overweight, $48 target — believes the platform thesis holds and branded GLP-1 ramp is the beginning of a new growth chapter
• BTIG: Buy, $60 target (cut from $85) — constructive on long-term platform, but acknowledged Q1 was worse than expected on margins
• JPMorgan: “Compelling path” post-Q1 — directionally positive on Novo/Lilly deal execution
• BofA: Neutral, $30 target — mixed quarter “resets Street expectations”; needs to see margin recovery before upgrading
• Citi: Sell, $30 target — structural concern that expanding Wegovy availability in retail pharmacies eliminates HIMS’s GLP-1 subscription premium

A spread from $30 to $60 on a single stock represents genuine disagreement about business model durability — not just about growth rates. That spread is your invitation to form an independent view.

My Take

I’ll be direct: HIMS is not a comfortable investment right now. Margin compression, regulatory overhang, an active lawsuit, and a new competitor in Amazon are all live risks simultaneously.

But the platform is more durable than the controversy suggests. Hair loss subscribers grew 45%+ for men, 170%+ for women (Q1 2025). Over 2.6 million people are paying a monthly subscription for health services through HIMS — and those subscribers didn’t sign up for semaglutide alone.

The 125,000 Wegovy shipments in six weeks show execution, not just intention. The international 969% revenue surge shows diversification is real. Former Netflix CFO buying the dip publicly in 2026 is a notable signal from someone who knows subscription-model economics intimately.

The compounding crisis exposed a real vulnerability: HIMS had become more dependent on GLP-1 revenue than it publicly acknowledged. The Q1 margin collapse proved that. But the response — securing direct branded partnerships with Novo Nordisk and Eli Lilly within weeks — showed organizational agility that matters.

My position: watchlist, not buy — yet. I’d want to see Q2 2026 gross margin recover toward 67%+ and subscriber count cross 2.7 million before building a position. If those two data points align in the August earnings release, the risk-reward shifts meaningfully in favor of a staged entry. I would not wait for a full margin recovery to the 73% pre-compounding level — that may never return — but 67% with a clear upward trend would confirm the branded model can sustain the business.

This is the kind of transition story that either looks obvious in hindsight or becomes a cautionary tale. The next two quarters will clarify which. Position sizing matters here: this is not a full-conviction core holding until execution is proved. A 2–3% portfolio weight with room to add is how I’d approach it.

---

This post is for informational purposes only and does not constitute investment advice. Investing in equities involves risk of loss.

Verified sources used: Hims & Hers Q1 2026 8-K earnings release (SEC EDGAR, May 2026); FY2025 results press release (investors.hims.com, February 2026); FDA GLP-1 compounding regulatory actions (National Law Review, Pharmacy Times, April–May 2026); Wall Street analyst actions (247WallSt, StockTwits, May 2026). Items left qualitative: exact current stock price and live market cap (not sourced from real-time feed).